TNFRSF17

Across TCGA pan-cancer cohorts, TNFRSF17 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of TNFRSF17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TNFRSF17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TNFRSF17 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where TNFRSF17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TNFRSF17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	+0.841	<.001	6	view →
LSCC	All	II,III,IV	+0.361	.002	6	view →
CCRCC	All	III,IV	−0.450	.006	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

TNFRSF17–LUAD

Open the LUAD breakdown →